Sarepta Therapeutics
SRPT
114 hedge funds and large institutions have $639M invested in Sarepta Therapeutics in 2014 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 47 increasing their positions, 32 reducing their positions, and 16 closing their positions.
47% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 32
38% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 16
13% more capital invested
Capital invested by funds: $563M → $639M (+$75.5M)
6% more funds holding
Funds holding: 108 → 114 (+6)
1% more call options, than puts
Call options by funds: $83M | Put options by funds: $82.1M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$38.7M |
| 2 |
PC
PointState Capital
New York
|
+$15.3M |
| 3 |
AGA
Altrinsic Global Advisors
Stamford,
Connecticut
|
+$4.84M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$2.99M |
| 5 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$2.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$17.3M |
| 2 |
PA
Perceptive Advisors
New York
|
-$15.4M |
| 3 |
BC
Broadfin Capital
New York
|
-$14.7M |
| 4 |
Capital Fund Management (CFM)
Paris,
France
|
-$7.53M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$6.39M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Jane Street
New York
| – | -$227K | -11,153 | Closed |
|
|
FNYS
127
First New York Securities
New York
| – | -$191K | -7,500 | Closed |
|
128
BNP Paribas Financial Markets
Paris,
France
| – | -$8.86K | -435 | Closed |
|
|
LTFS
129
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$6K | -300 | Closed |
|
|
TRCT
130
Tower Research Capital (TRC)
New York
| – | -$2K | -118 | Closed |
|
SRPT Hedge Fund Activity: Q1 2014 in Review
114 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q1 2014, worth a combined $639M — up 13% from $563M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new SRPT positions and 16 closed out — a net gain of 6 holders — while 47 added to existing stakes and 32 trimmed.
The largest buyer was Lord, Abbett & Co, adding an estimated $38.7M. The largest seller was Visium Asset Management, exiting entirely with an estimated $17.3M sold.
- 114 institutional investors held Sarepta Therapeutics (SRPT) as of Q1 2014, up from 108 in Q4 2013.
- Funds reported $639M of Sarepta Therapeutics stock for Q1 2014, up 13% quarter-over-quarter.
- 22 funds opened new Sarepta Therapeutics positions in Q1 2014 and 16 closed out, a net change of +6 holders.
- The largest Sarepta Therapeutics buyer in Q1 2014 was Lord, Abbett & Co, an estimated $38.7M added.
- The largest Sarepta Therapeutics seller in Q1 2014 was Visium Asset Management, an estimated $17.3M sold.
Based on aggregated 13F filings for Q1 2014.